Navigation Links
Previously unseen switch regulates breast cancer response to estrogen
Date:5/8/2008

A tiny modification called methylation on estrogen receptors prolongs the life of these growth-driving molecules in breast cancer cells, according to research by scientists at Emory University's Winship Cancer Institute.

The results are published in the May 9, 2008 issue of the journal Molecular Cell.

Most breast cancers contain estrogen receptors, which enable them to grow in the presence of the hormone estrogen. Their presence can determine whether tumors will respond to the estrogen-blocking drug tamoxifen.

The finding will help researchers sort out how mutations change the estrogen receptor's function and allow some breast cancers to resist tamoxifen, says Paula Vertino, PhD, associate professor of radiation oncology at Emory University School of Medicine.

"The problem is that a significant fraction of estrogen receptor positive tumors don't respond to tamoxifen," Vertino says. "Development of new drugs that interfere with the methylation of the estrogen receptor may be an alternative way to treat those tumors."

Until recently, scientists thought methylation enzymes acted only on DNA molecules or on histones, proteins that bundle DNA into spool-like packages. Methylation enzymes add tags called methyl groups to other molecules, influencing their ability to turn genes on or off.

Vertino and her colleagues found that one of the modification enzymes, called SET7, methylates a flexible part of the estrogen receptor. When they created breast cancer cells with reduced levels of SET7, the estrogen receptor molecules lasted only half as long and were less effective in turning on genes.

Vertino's team showed that a mutation in the estrogen receptor found in more aggressive breast tumors interferes with methylation in cells. Also, the methylation appears in exactly the same spot where another protein called BRCA1 adds a different kind of regulatory marking, and may block BRCA1's restrictive effects on the estrogen receptor.

Women who inherit a mutation in the gene that encodes BRCA1 have up to an 80 percent lifetime risk of developing breast cancer, several times the risk of those who don't have it, according to the National Cancer Institute. BRCA1 mutations are estimated to account for about a third of all inherited breast cancers and roughly 2-3 percent of all breast cancers.

Scientists are beginning to look for drugs that could modulate methylation enzymes. Vertino says that methylation probably affects several other proteins similar to the estrogen receptor.

"I expect this will be just the tip of the iceberg," she says. "Methylation may be just as common as other protein modifications, and even more complicated."


'/>"/>

Contact: Vince Dollard
vdollar@emory.edu
404-778-4580
Emory University
Source:Eurekalert

Related medicine news :

1. Brain cells work differently than previously thought
2. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
3. New transfusion rules restrict donations from previously pregnant women
4. Z Trim Holdings Reports Restatement of Previously Issued Financial Statements; Amends Bylaws
5. CDC Reports Prevalence of Worms Transmitted by Dogs and Cats to Humans is Higher Than Previously Understood
6. China Sky One Medical Completes Previously Announced Amendment to 2006 Form 10KSB
7. Symmetry Medical Provides Update of Previously Disclosed Accounting Review at Sheffield, UK Operating Unit
8. More functional DNA in genome than previously thought
9. The Ensign Group, Inc. Acquires Assets of Three Previously Leased Facilities
10. HealthSouth Announces Final Agreement on Previously Disclosed Settlement with Federal Government
11. China Sky One Medical Completes Previously Announced Amendments to Form 10QSB for the Second and Third Quarters of 2006
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Guruji Mahendra ... 9th, 10th and 11th, 2016 in honor of his birthday on February 10th. ... happiness. Mahendra Trivedi is known by over 250,000 people from over 40 different ...
(Date:2/7/2016)... ... February 07, 2016 , ... Women’s Excellence now ... the most minimally invasive approaches. , Women who have had multiple vaginal births ... factors include surgery to the pelvic floor, connective tissue disorders, and obesity. Women ...
(Date:2/7/2016)... ... February 07, 2016 , ... Dr. Todd Hobgood , ... medical and surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, ... non-surgical alternative for reduction of fat below the chin (aka the “double chin”). ...
(Date:2/6/2016)... ... February 06, 2016 , ... With the FCPX ... warm color grades to their footage. A LUT is a Lookup Table that contains ... the corresponding color indicated by the table. By manipulating each pixel, LUT's can change ...
(Date:2/5/2016)... ... , ... Steven Tonkinson, 36, of Coconut Grove, Florida, ran the Miami Marathon ... 2003. This year, he ran all 26.2 miles with a green 25-pound ShelterBox strapped ... Heat. , This Sunday, while many are watching the Superbowl, Steven Tonkinson will strap ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... -- HemaFlo Therapeutics, Inc. announced today that the United States Patent ... covering the use of NephroFlow to treat acute kidney injury ... said, "We are pleased to secure our rights to such ... PhD, HemaFlo,s founder, said, "We are pleased to secure our ... Dale Peterson , PhD, HemaFlo,s founder, said, "We are ...
(Date:2/8/2016)... , Feb. 8, 2016  Dynatronics Corporation ... of advanced-technology medical devices and rehabilitation equipment for ... congratulates the Denver Broncos, football team for winning ... Cullimore Jr. , Chairman and Chief Executive Officer.  ... and we look forward to enhancing their athletic ...
(Date:2/8/2016)... , Feb. 8, 2016  Sangamo BioSciences, ... therapeutic genome editing, announced that the U.S. Food ... Investigational New Drug (IND) application for SB-318, a ... therapy for Mucopolysaccharidosis Type I (MPS I). The ... Sangamo to initiate a Phase 1/2 clinical study ...
Breaking Medicine Technology: